Market research
NLZ.F NeuroMetrix, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 531K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 2.31
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US6412558073
- Market cap
- 531K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 2.31
About
About NeuroMetrix, Inc
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NLZ.F discussion.
5 years, 5 months ago
NeuroMetrix, Inc is currently in a long term uptrend where the price is trading 12.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
NeuroMetrix, Inc's total revenue rose by 6.0% to $2M since the same quarter in the previous year.
Its net income has increased by 69.2% to $-326K since the same quarter in the previous year.
Finally, its free cash flow grew by 513.3% to $281K since the same quarter in the previous year.
Based on the above factors, NeuroMetrix, Inc gets an overall score of 5/5.